mesalamine

Summary

Summary: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)

Top Publications

  1. ncbi Colorectal cancer prevention in ulcerative colitis: a case-control study
    J Eaden
    The Gastrointestinal Research Unit, Leicester General Hospital, Leicester, UK
    Aliment Pharmacol Ther 14:145-53. 2000
  2. pmc PPARgamma as a new therapeutic target in inflammatory bowel diseases
    L Dubuquoy
    INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
    Gut 55:1341-9. 2006
  3. pmc Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis
    Jeffrey B Brown
    Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Gastroenterology 138:595-605, 605.e1-3. 2010
  4. ncbi The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway
    Johanna Munding
    Institute of Pathology, Ruhr University Bochum, D 44789, Germany
    Carcinogenesis 33:637-43. 2012
  5. ncbi 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations
    Geoffrey C Nguyen
    Mount Sinai Hospital Centre for Inflammatory Bowel Disease, University of Toronto, Toronto, Ontario, Canada
    Am J Gastroenterol 107:1298-304; quiz 1297, 1305. 2012
  6. ncbi Mesalamine protects against colorectal cancer in inflammatory bowel disease
    Jeffrey Tang
    Department of Internal Medicine, Division of Gastroenterology, Henry Ford Health System, Henry Ford Hospital, Detroit, MI 48202, USA
    Dig Dis Sci 55:1696-703. 2010
  7. pmc Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1
    Vineeta Khare
    Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology and Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Vienna, Austria
    Biochem Pharmacol 85:234-44. 2013
  8. ncbi Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells
    G Monteleone
    Dipartimento di Medicina Interna, Cattedra di Gastroenterologia e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, University Tor Vergata of Rome, Rome, Italy
    Cell Death Differ 13:202-11. 2006
  9. pmc Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis
    S Fiorucci
    Department of Gastroenterology, University of Perugia, Perugia, Italy
    Br J Pharmacol 150:996-1002. 2007
  10. ncbi Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
    Fernando S Velayos
    Division of Gastroenterology and UCSF Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94143, USA
    Am J Gastroenterol 100:1345-53. 2005

Detail Information

Publications289 found, 100 shown here

  1. ncbi Colorectal cancer prevention in ulcerative colitis: a case-control study
    J Eaden
    The Gastrointestinal Research Unit, Leicester General Hospital, Leicester, UK
    Aliment Pharmacol Ther 14:145-53. 2000
    ..The risk of colorectal cancer (CRC) in ulcerative colitis (UC) increases with extent and duration of disease. Identifying other risk factors would allow targeting of sub-groups at greatest risk, enabling more cost-effective surveillance...
  2. pmc PPARgamma as a new therapeutic target in inflammatory bowel diseases
    L Dubuquoy
    INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
    Gut 55:1341-9. 2006
    ..The aims of this review are to discuss the potential roles of PPARgamma in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor...
  3. pmc Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis
    Jeffrey B Brown
    Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Gastroenterology 138:595-605, 605.e1-3. 2010
    b>Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)...
  4. ncbi The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway
    Johanna Munding
    Institute of Pathology, Ruhr University Bochum, D 44789, Germany
    Carcinogenesis 33:637-43. 2012
    ..Therefore, we suggest the use of 5-ASA as a promising drug for prevention of sporadic colorectal carcinoma...
  5. ncbi 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations
    Geoffrey C Nguyen
    Mount Sinai Hospital Centre for Inflammatory Bowel Disease, University of Toronto, Toronto, Ontario, Canada
    Am J Gastroenterol 107:1298-304; quiz 1297, 1305. 2012
    ..However, more recent population-based studies suggest no protective association. We conducted a systematic review that focused on non-referral studies to reassess the role of 5-ASA for this indication...
  6. ncbi Mesalamine protects against colorectal cancer in inflammatory bowel disease
    Jeffrey Tang
    Department of Internal Medicine, Division of Gastroenterology, Henry Ford Health System, Henry Ford Hospital, Detroit, MI 48202, USA
    Dig Dis Sci 55:1696-703. 2010
    ..Previous studies show this risk is strongly associated with dysplasia, extent of disease, duration of disease, and degree of inflammation, while chemoprevention of CRC has less support...
  7. pmc Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1
    Vineeta Khare
    Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology and Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Vienna, Austria
    Biochem Pharmacol 85:234-44. 2013
    b>Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon...
  8. ncbi Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells
    G Monteleone
    Dipartimento di Medicina Interna, Cattedra di Gastroenterologia e Centro di Eccellenza per lo studio delle malattie complesse e multifattoriali, University Tor Vergata of Rome, Rome, Italy
    Cell Death Differ 13:202-11. 2006
    ..Finally, we show that 5-ASA attenuates p-EGFR in ex vivo organ cultures of CRC explants. Data indicate that 5-ASA disrupts EGFR signalling by enhancing SH-PTP2 activity, and suggest a mechanism by which 5-ASA interferes with CRC growth...
  9. pmc Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis
    S Fiorucci
    Department of Gastroenterology, University of Perugia, Perugia, Italy
    Br J Pharmacol 150:996-1002. 2007
    b>Mesalamine is the first-line therapy for colitis, but it lacks potency and is only effective for mild-to-moderate forms of this disease...
  10. ncbi Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
    Fernando S Velayos
    Division of Gastroenterology and UCSF Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94143, USA
    Am J Gastroenterol 100:1345-53. 2005
    ..We performed a systematic review with metaanalysis of observational studies evaluating the association between 5-ASA use and colorectal cancer (CRC) or dysplasia among patients with ulcerative colitis...
  11. ncbi Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study
    R Corinaldesi
    Department of Clinical Medicine and Center for Applied Biomedical Research, University of Bologna, Bologna, Italy
    Aliment Pharmacol Ther 30:245-52. 2009
    ..Intestinal immune infiltration contributes to symptoms in patients with irritable bowel syndrome (IBS)...
  12. pmc Medications as a source of human exposure to phthalates
    Russ Hauser
    Department of Environmental Health, Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Environ Health Perspect 112:751-3. 2004
    ..we report on medications as a potential source of exposure to DBP in a man who took Asacol [active ingredient mesalamine (mesalazine)] for the treatment of ulcerative colitis...
  13. ncbi Systematic review: adherence issues in the treatment of ulcerative colitis
    S V Kane
    Section of Gastroenterology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Aliment Pharmacol Ther 23:577-85. 2006
    ..It is a combination of understanding patient behaviour, recognizing signs of non-adherent behaviour and utilizing management strategies to change behaviour that will improve patient outcomes...
  14. ncbi Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis
    Sunanda Kane
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 18:1026-33. 2012
    ..to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX) mesalamine. A secondary outcome was the relationship between long-term efficacy and adherence.
  15. ncbi 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study
    Charles N Bernstein
    University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada
    Am J Gastroenterol 106:731-6. 2011
    ..We aimed to determine if use of 5-aminosalicylates (5-ASA) was associated with a reduced risk of colorectal cancer (CRC) in people with inflammatory bowel disease (IBD)...
  16. ncbi Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials
    Stephen B Hanauer
    University of Chicago Pritzker School of Medicine, Illinois, USA
    Clin Gastroenterol Hepatol 2:379-88. 2004
    The aim of this study was to perform a meta-analysis of the efficacy results from 3 placebo-controlled multicenter clinical trials of slow-release mesalamine (Pentasa) for the acute treatment of mild to moderate Crohn's disease.
  17. ncbi Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells
    S Parenti
    Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    Aliment Pharmacol Ther 31:108-19. 2010
    ..A recent observation has suggested that inhibition of beta-catenin signalling could induce these cellular effects...
  18. ncbi Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations
    Runi A Foster
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    Inflamm Bowel Dis 9:308-15. 2003
    Lung injury related to mesalamine (5-aminosalicylic acid) has rarely been reported in patients with inflammatory bowel diseases...
  19. pmc Mesalazine reduces mutations in transforming growth factor beta receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats
    Christoph Campregher
    Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 16:1950-6. 2010
    ..Here, we tested the effect of 5-ASA on replication fidelity in mononucleotide, dinucleotide, and tetranucleotide repeats...
  20. ncbi Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity
    Carina L Bos
    Laboratory of Experimental Oncology and Radiobiology, Department of Oncology, University of Amsterdam, The Netherlands
    Carcinogenesis 27:2371-82. 2006
    ..This study shows, using concentrations of mesalazine identical to concentrations seen in patients with inflammatory bowel disease, that mesalazine inhibits the Wnt/beta-catenin pathway via inhibition of PP2A...
  21. ncbi Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid
    Carmine Stolfi
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
    Biochem Pharmacol 75:668-76. 2008
    ..Taken together our data indicate that 5-ASA causes both a COX-2-dependent and -independent inhibition of CRC cell growth...
  22. ncbi Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis
    Takayuki Yamamoto
    Inflammatory Bowel Disease Centre, Yokkaichi Social Insurance Hospital, Yokkaichi, Mie, Japan
    J Crohns Colitis 6:750-5. 2012
    ..This study was to see if the introduction of GMA at an early stage reduces corticosteroid administration and steroid dependency in the long term clinical course of UC...
  23. ncbi Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study
    Fabrizio Bossa
    UU OO Gastroenterologia ed Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    Am J Gastroenterol 103:2509-16. 2008
    ..We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P) encapsulated into erythrocytes (DEE)...
  24. ncbi Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis
    Geert D'Haens
    Academic Medical Center, Amsterdam, The Netherlands
    Am J Gastroenterol 107:1064-77. 2012
    Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy...
  25. ncbi 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer
    Bart Baan
    Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, Amsterdam, The Netherlands
    Gut 61:1708-15. 2012
    ..In vitro data suggest that, in colorectal cancer cells, 5-ASA induces cell cycle arrest, but the molecular mechanism leading to this arrest remains to be determined...
  26. ncbi Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
    Cochrane Database Syst Rev 10:CD000544. 2012
    ..This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis...
  27. ncbi High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials
    Tessa E H Römkens
    Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Inflamm Bowel Dis 18:2190-8. 2012
    ..The aim of this study was to systematically review the medical literature in order to compare different preparations of 5-ASA for the effect on MH...
  28. ncbi Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase
    Carmine Stolfi
    Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Carcinogenesis 29:1258-66. 2008
    ..Data show that mesalazine negatively regulates CDC25A protein expression, thus delaying CRC cell progression...
  29. pmc Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
    P W Lowry
    Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Gut 49:656-64. 2001
    AIM: We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine...
  30. ncbi Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine
    A Lyakhovich
    Department of Medicine, Medical University of Vienna, Austria
    Aliment Pharmacol Ther 31:202-9. 2010
    Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis...
  31. ncbi Inflammatory bowel disease: clinical aspects and established and evolving therapies
    Daniel C Baumgart
    Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
    Lancet 369:1641-57. 2007
    ..Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects...
  32. ncbi Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
    Matthew Rutter
    Department of Gastroenterology, University Hospital of North Tees, Stockton on Tees, Teesside, England
    Gastroenterology 126:451-9. 2004
    ..Patients with ulcerative colitis are at increased risk of colorectal cancer. It is widely believed that this is secondary to colonic inflammation. However, the severity of colonic inflammation has never been shown to be a risk factor...
  33. ncbi Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease
    Reikei Matsuda
    Department of Internal Medicine, Fujisawa Shounandai Hospital, Fujisawa, Kanagawa, Japan
    Inflamm Bowel Dis 15:328-34. 2009
    ..This study was to investigate the expressions of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 mRNAs in the colonic mucosa of patients with ulcerative colitis (UC) during active and quiescent UC...
  34. ncbi Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity
    L J Egan
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Biol Chem 274:26448-53. 1999
    ..In this report, we demonstrate that mesalamine, an anti-inflammatory aminosalicylate, dose-dependently inhibits IL-1-stimulated NF-kappaB-dependent ..
  35. ncbi 5-Aminosalicylic acid inhibits TGF-beta1 signalling in colorectal cancer cells
    Pim J Koelink
    Department of Gastroenterology Hepatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Cancer Lett 287:82-90. 2010
    ..We conclude that 5-ASA inhibits TGF-beta1 signalling in colorectal cancer cells, and might be a potent adjuvant therapeutic drug, interfering with aberrant TGF-beta signalling in colorectal cancer...
  36. pmc Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs
    S G Nugent
    Department of Surgery, St George's Hospital Blackshaw Road, London, UK
    Gut 48:571-7. 2001
    ..This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies...
  37. ncbi Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
    P D R Higgins
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    Aliment Pharmacol Ther 29:247-57. 2009
    ..Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis...
  38. ncbi Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 138:1286-96, 1296.e1-3. 2010
    ..This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients.
  39. ncbi 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity
    Eleonora Distrutti
    Clinica di Gastroenterologia, Policlinico Monteluce, University of Perugia, Via Enrico Dal Pozzo, 06122 Perugia, Italy
    J Pharmacol Exp Ther 319:447-58. 2006
    ..In this study, we have investigated the role of a novel H(2)S-releasing derivative of mesalamine (5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester, ATB-429) in modulating nociception ..
  40. ncbi Nonadherence in inflammatory bowel disease: results of factor analysis
    Petr Cerveny
    Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic
    Inflamm Bowel Dis 13:1244-9. 2007
    ..The purpose of the study was to assess overall nonadherence to treatment among patients with Crohn's disease (CD) and ulcerative colitis (UC) in a single tertiary center...
  41. pmc Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
    P Marteau
    Gastroenterology, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    Gut 54:960-5. 2005
    ....
  42. ncbi Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 137:1934-43.e1-3. 2009
    It is not clear what induction dose of mesalamine is optimal for treating patients with mildly and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4...
  43. ncbi Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial
    Stephen B Hanauer
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Gastroenterology 127:723-9. 2004
    ..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after ..
  44. ncbi PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells
    Markus Schwab
    First Department of Medicine ZAFES, Johann Wolfgang Goethe University Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Carcinogenesis 29:1407-14. 2008
    ..The aim of our study was to investigate the involvement of peroxisome proliferator-activated receptor gamma (PPARgamma) in mesalazine's anticarcinogenic actions in colorectal cancer cells...
  45. ncbi Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes
    Nielsen Q Fernandez-Becker
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Drugs 68:1089-103. 2008
    ..The development of delivery methods that allow once-daily administration represents a potential means to improve the low medication adherence rates reported in patients with ulcerative colitis...
  46. pmc Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
    Christel Rousseaux
    Institut National de la Santé et de la Recherche Medicale 0114, Physiopathologie des Maladies Inflammatoires Intestinales, CHU 59037 Lille, France
    J Exp Med 201:1205-15. 2005
    ..Validation of these results was obtained with organ cultures of human colonic biopsies. These data identify PPAR-gamma as a target of 5-ASA underlying antiinflammatory effects in the colon...
  47. ncbi Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells
    A Reinacher-Schick
    Department of Medicine, Ruhr University Bochum, Knappschaftskrankenhaus, Germany
    Carcinogenesis 24:443-51. 2003
    ..These findings may suggest a potential of mesalazine as a chemopreventive agent for colorectal cancer...
  48. ncbi Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis
    Michael A Kamm
    St Vincent s Hospital, Department of Medicine, University of Melbourne, Melbourne, Australia
    Inflamm Bowel Dis 15:1-8. 2009
    Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies...
  49. ncbi 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis
    Margie L Clapper
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Inflamm Bowel Dis 14:1341-7. 2008
    ..The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia...
  50. ncbi 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes
    Pim J Koelink
    Department of Gastroenterology and Hepatology, and Leiden University Medical Center, Leiden, The Netherlands
    Inflamm Bowel Dis 16:379-89. 2010
    ....
  51. ncbi Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis
    Linnette Yen
    Global Health Economics and Outcomes Research, Shire Development LLC, 725 Chesterbrook Blvd, Wayne, PA 19087, USA
    J Manag Care Pharm 18:701-12. 2012
    ..5-aminosalicylic acid (5-ASA) is the recommended first-line treatment for active mild-to-moderate ulcerative colitis (UC) and for maintenance of UC remission. However, persistence and adherence to prescribed 5-ASAs are often suboptimal...
  52. pmc Solitary rectal ulcer syndrome in children and adolescents
    Emily R Perito
    Department of Pediatrics, University of California, San Francisco, CA 94143 0136, USA
    J Pediatr Gastroenterol Nutr 54:266-70. 2012
    ..The aim of this study was to describe the presenting symptoms, endoscopic and histologic findings, and clinical courses of pediatric patients diagnosed with solitary rectal ulcer syndrome (SRUS)...
  53. ncbi Review article: Oral, modified-release mesalazine formulations--proprietary versus generic
    A Forbes
    St Mark s Academic Institute, St Mark s Hospital, Northwick Park, Harrow, UK
    Aliment Pharmacol Ther 17:1207-14. 2003
    ..Of most importance here is that the assessment of new modified-release products is sufficiently rigorous to allow patients and physicians to be confident in their use...
  54. ncbi Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid
    Ruedeekorn Wiwattanapatapee
    Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkla 90112, Thailand
    J Control Release 88:1-9. 2003
    ..Only a small amount of 5-ASA was found after incubation of both conjugates with the homogenate of the small intestine for 12 h. It appears that this PAMAM dendrimer can be developed for use as a carrier for colon-specific drug delivery...
  55. ncbi Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose
    Nabeel Khan
    Department of Internal Medicine, Section of Gastroenterology, Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, USA
    Inflamm Bowel Dis 19:1123-9. 2013
    There are limited data about the long-term follow-up of patients with ulcerative colitis (UC) maintained on high versus low doses of mesalamine. We evaluated the best long-term average daily dose that would keep the disease in remission.
  56. ncbi The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity
    Christoph Campregher
    Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, and Christian Doppler Laboratory on Molecular Cancer Chemoprevention, Vienna, Austria
    Inflamm Bowel Dis 16:576-82. 2010
    ..So far neither 5-ASA's structural specificity nor its pharmacophore group have been identified. Here we compared 5-ASA with its analogs (4-ASA and 3-ASA) and its metabolite N-acetyl-5-ASA (NAc-5-ASA)...
  57. pmc Mesalamine in the treatment and maintenance of remission of ulcerative colitis
    Maggie Ham
    Center for Inflammatory Bowel Disease, BIDMC Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Expert Rev Clin Pharmacol 5:113-23. 2012
    ..b>Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-..
  58. ncbi Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study
    O A Paoluzi
    Gastroenterology Unit, Department of Clinical Science, La Sapienza University, Rome, Italy
    Aliment Pharmacol Ther 21:1111-9. 2005
    ..Mesalazine as maintenance therapy in ulcerative colitis is used worldwide and has been proven to be effective. However, the optimal dosage remains to be defined...
  59. ncbi Novel prodrugs for the treatment of colonic diseases based on 5-aminosalicylic acid, 4'-geranyloxyferulic acid, and auraptene: biological activities and analytical assays
    Francesco Epifano
    Universita degli Studi G D Annunzio, Chieti Pescara, Facolta di Farmacia, Dipartimento di Scienze del Farmaco, Via dei Vestini 31, 66100 Chieti CH, Italy
    Curr Drug Deliv 9:112-21. 2012
    ....
  60. ncbi The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Western University, London, Ontario, Canada
    Gastroenterology 145:149-157.e2. 2013
    ..Interobserver differences in endoscopic assessments contribute to variations in rates of response to placebo in ulcerative colitis (UC) trials. We investigated whether centralized review of images could reduce these variations...
  61. ncbi Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats
    Hanumantha R Ancha
    Division of Gastroenterology, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Dig Dis Sci 54:758-66. 2009
    ..studies was to examine mechanisms by which the rectally administered combination of N-acetylcysteine (NAC) plus mesalamine (5-ASA) affects inducers of inflammation to promote mucosal healing and reduce tissue inflammation in chemically ..
  62. pmc Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis
    G Frieri
    Cattedra di Gastroenterologia, Universita di L Aquila, L Aquila, Italy
    Gut 47:410-4. 2000
    ..The treatment of ulcerative colitis (UC) with 5-aminosalicylic acid (5-ASA) does not have the same therapeutic effect in all patients. We tested the hypothesis that the effectiveness of the drug is related to its mucosal concentration...
  63. ncbi Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment
    G Frieri
    Gastroenterology Unit, University of L Aquila, Italy
    Aliment Pharmacol Ther 13:1413-7. 1999
    ..To measure mucosal concentrations of mesalazine in ulcerative colitis patients treated with oral mesalazine alone, compared to patients treated with both topical and oral mesalazine...
  64. ncbi Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study
    Ashok K Tuteja
    Division of Gastroenterology, University of Utah, School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132, USA
    Scand J Gastroenterol 47:1159-64. 2012
    ..There is often an increase in sub-epithelial inflammatory and neuroendocrine cells on colonic mucosal biopsy. Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease...
  65. ncbi A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study
    Anne E Gifford
    Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 108:249-55. 2013
    b>Mesalamine non-adherence is common among patients with ulcerative colitis (UC), and can be difficult to identify in practice...
  66. doi Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis
    Sundae Stelts
    Ann Pharmacother 42:904-5. 2008
  67. ncbi Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system
    N Khan
    Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA
    Aliment Pharmacol Ther 36:755-64. 2012
    ..Adherence is a major factor in determining disease activity in ulcerative colitis (UC). There are limited data on long-term nationwide adherence levels among patients with UC...
  68. ncbi Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis
    Paul L McCormack
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:2635-42. 2007
    ..Two of 434 MMX mesalazine recipients experienced serious adverse events that were considered treatment related (pancreatitis caused by mesalazine sensitivity)...
  69. ncbi Mesalamine delivery systems: do they really make much difference?
    Altamash I Qureshi
    Department of Internal Medicine, Wayne State University, Detroit Medical Center, USA
    Adv Drug Deliv Rev 57:281-302. 2005
    ..aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel...
  70. ncbi Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pellets
    Ehab R Bendas
    Department of Pharmaceutics, College of Pharmacy, Oregon State University, Corvallis, OR, USA
    Drug Dev Ind Pharm 36:393-404. 2010
    ..The basic objective of this study was to develop a novel technique that aids in compaction of coated pellets into tablets and obtain a release pattern from compressed pellets resembling the same pattern before compression...
  71. ncbi Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis
    W Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Germany
    Aliment Pharmacol Ther 33:313-22. 2011
    Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining remission in ulcerative colitis are limited.
  72. ncbi Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers
    W J Sandborn
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 19:1089-98. 2004
    Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid ..
  73. ncbi Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
    Peter Laszlo Lakatos
    1st Department of Medicine, Semmelweis University, Koranyi S 2A, H 1083 Budapest, Hungary
    Pharmacol Res 58:190-5. 2008
    ..In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once daily mesalazine formulations...
  74. ncbi Current concept of pathophysiological understanding and natural course of ulcerative colitis
    Martin H Holtmann
    Department of Medicine, Johannes Gutenberg University, Langenbeckstrasse 1, 55131 Mainz, Germany
    Langenbecks Arch Surg 389:341-9. 2004
    ....
  75. ncbi Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers
    Thai Hoa Joeres-Nguyen-Xuan
    Evangelisches Krankenhaus Kalk, Cologne, Germany
    Inflamm Bowel Dis 16:256-62. 2010
    b>Mesalamine and the probiotic E. coli Nissle 1917 (EcN) are both effective agents for the treatment of ulcerative colitis. A combined therapy may have more than additive efficacy. However, mesalamine may have antimicrobial effects on EcN.
  76. pmc One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis
    A Barney Hawthorne
    Department of Medicine, University Hospital of Wales, Cardiff, UK
    Inflamm Bowel Dis 18:1885-93. 2012
    ..We aimed to investigate whether OD Asacol was as effective as three times (TDS) daily dosing, and to evaluate the role of treatment adherence...
  77. ncbi Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse
    S R Ritland
    Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona 85259, USA
    Clin Cancer Res 5:855-63. 1999
    ....
  78. ncbi Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
    B J Rembacken
    Centre for Digestive Diseases, The General Infirmary at Leeds, UK
    Lancet 354:635-9. 1999
    ..coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E. coli to standard medical therapy increased the chance of remission of active ulcerative colitis...
  79. ncbi Small intestinal release mesalamine for the treatment of refractory celiac disease type I
    Shailaja Jamma
    Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Clin Gastroenterol 45:30-3. 2011
    The goal of this study is to evaluate the safety and efficacy of Small intestinal release mesalamine (SIRM) for symptom relief in refractory celiac disease (RCD).
  80. ncbi Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease
    A Prakash
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 57:383-408. 1999
    ..4 g/day is effective in preventing postoperative recurrence of Crohn's disease. Oral delayed-release mesalazine is effective and well tolerated in sulfasalazine-intolerant patients with ulcerative colitis or Crohn's disease...
  81. ncbi Clinical pharmacokinetics of slow release mesalazine
    M De Vos
    Department of Gastroenterology, Ghent University Hospital, Belgium
    Clin Pharmacokinet 39:85-97. 2000
    ..Although preliminary data support an association between mucosal concentrations of mesalazine and its clinical activity, further studies are needed to correlate the effects of this drug with its pharmacokinetic parameters...
  82. pmc Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study
    Hiroaki Ito
    Digestive Disease Center of Excellence, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
    Inflamm Bowel Dis 16:1567-74. 2010
    b>Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC.
  83. pmc Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents
    Melvin B Heyman
    Department of Pediatrics, University of California, San Francisco, California 94143 0136, USA
    Inflamm Bowel Dis 16:1931-9. 2010
    ..We conducted an open-label trial to evaluate the clinical efficacy of a mesalamine suppository (500 mg) to treat pediatric patients with mild to moderate ulcerative proctitis.
  84. ncbi Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis
    Alexander C Ford
    Leeds Gastroenterology Institute, Leeds General Infirmary, UK
    Am J Gastroenterol 106:2070-7; quiz 2078. 2011
    ..Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue...
  85. ncbi Mesalamine for inflammatory bowel disease: recent reappraisals
    Giovanni C Actis
    Department of Gastro Hepatology, Ospedale Gradenigo, Torino, Italy
    Inflamm Allergy Drug Targets 7:1-5. 2008
    Derived from the historical molecule sulfasalazine, mesalamine has remained one of the mainstays for treatment of inflammatory bowel disease in the last 50 years...
  86. ncbi Mesalamine derivatives in the treatment of Crohn's disease
    Laura E Harrell
    Section of Gastroenterology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637, USA
    Gastroenterol Clin North Am 33:303-17, ix-x. 2004
    ..It remains to be determined whether certain high-risk groups of patients may benefit from higher doses of mesalamine induction or maintenance therapy. Mesalamine derivatives are also of benefit in the treatment of Crohn's disease...
  87. ncbi Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 6:97-105. 2006
    Sulfasalazine, olsalazine, balsalazide, delayed-release mesalamine, controlled-release mesalamine, mesalamine pellets, and Multi-Matrix System mesalamine are effective first-line therapies for the treatment of mildly to moderately active ..
  88. ncbi A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective
    Nic Brereton
    School of Health and Related Research ScHARR, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
    J Med Econ 13:148-61. 2010
    ..To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective...
  89. ncbi Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis
    L P Piodi
    U O di Gastroenterologia, Servizio di Medicina Nucleare, Milan, Italy
    Scand J Gastroenterol 39:154-7. 2004
    ..Both the efficacy of long-term intermittent therapy with low-dose 5-ASA enemas in preventing UC relapses and its economic implications were evaluated...
  90. ncbi The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine
    Wolfgang Kruis
    Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany
    Clin Gastroenterol Hepatol 1:36-43. 2003
    ..A new pellet preparation was designed combining slow and delayed release properties. Aims of the study were to find the optimal dose and to test efficacy and safety of a new 5-aminosalicylic acid formulation...
  91. ncbi A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis
    John I Mackowiak
    Center for Outcomes Research, Chapel Hill, North Carolina 27517, USA
    Manag Care Interface 19:39-46, 56. 2006
    ..results from clinical trials directly comparing oral balsalazide capsules and a specific formulation of oral mesalamine. Health care costs related to UC for an oral 5-ASA failure is greater than dollar 11,500 on average in the first ..
  92. ncbi Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 12:979-94. 2006
    ..The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement...
  93. ncbi Diagnosis and treatment of ulcerative proctitis
    Miguel D Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pennsylvania 15212, USA
    J Clin Gastroenterol 38:733-40. 2004
    ..This review highlights the pathogenesis, diagnosis, and treatment of ulcerative proctitis...
  94. ncbi Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteers
    Kenji Tokui
    Department of Pharmacy, Nagoya Daini Red Cross Hospital, Japan
    Biol Pharm Bull 25:264-7. 2002
    ..The present findings suggest that 5-ASA has favorable absorptive properties and can be expected to have systemic action after rectal administration of a 5-ASA enema...
  95. ncbi Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing
    T B Vree
    Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, Nijmegen, The Netherlands
    J Pharm Pharmacol 52:645-52. 2000
    ..8% metabolite with I and 15.5% with II. The renal clearance of the metabolite acetylmesalazine was independent of the observed defecation patterns (300 mL min(-1), P > 0.8), stool composition, and type of absorption...
  96. ncbi Ulcerative proctitis: a review of pharmacotherapy and management
    Peter Laszlo Lakatos
    Semmelweis University, First Department of Medicine, H1083 Budapest, Koranyi S 2A, Hungary
    Expert Opin Pharmacother 9:741-9. 2008
    ..Ulcerative proctitis (UP) is a common presentation of ulcerative colitis (UC)...
  97. pmc Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates
    Joel H Rubenstein
    The Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 104:2222-32. 2009
    ..Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs...
  98. ncbi Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis
    Antonio Tursi
    Digestive Endoscopy Unit, Lorenzo Bonomo Hospital, Andria BA, Italy
    Med Sci Monit 10:PI126-31. 2004
    ..25 g/day) plus 3 g/day VLS#3 (group A) with medium-dose balsalazide alone (group B) and with mesalazine (group C) in the treatment of mild-to-moderate active ulcerative colitis...
  99. ncbi Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine
    Carmine Stolfi
    Department of Internal Medicine, University of Tor Vergata, Rome, Italy
    Gastroenterology 138:221-30. 2010
    b>Mesalamine has been reported to protect against inflammatory bowel disease-related colorectal cancer (CRC), but several drug-related issues have limited its use in chemopreventive programs...
  100. ncbi Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis
    Antoine Cortot
    Gastroenterologie, Hopital Claude Huriez, Lille, France
    Am J Gastroenterol 103:3106-14. 2008
    To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).
  101. ncbi Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs
    William N Tindall
    Department of Family Medicine, Wright State University, Dayton, Ohio, USA
    J Manag Care Pharm 13:S2-12; quiz S13-4. 2007
    ..Continued disease progression and relapse of UC over time are associated with an increased risk of colorectal cancer (CRC)...

Research Grants32

  1. New drug VS-110 for treating inflammatory bowel diseases
    Jinshyun Ruth Wu-Wong; Fiscal Year: 2013
    ..Currently drugs for anti-inflammatory diseases in the GI tract such as mesalamine (Asacol, Lialda, Pentasa) and budesonide achieved US$2.9 billion in annual worldwide sales in 2011...
  2. CAT1920: A Small Molecule Therapeutic for the Treatment of IBD
    MICHAEL ROBERT JIROUSEK; Fiscal Year: 2010
    ..The proposal presented in this Phase I SBIR grant application will establish the mechanism of action of CAT1920 and its utility as a novel, safe and efficacious therapeutic for the treatment of IBD. ..
  3. Predicting Response to Standardized Pediatric Colitis Therapy: The PROTECT Study
    Mi Ok Kim; Fiscal Year: 2011
    ..for a clinical trial of early IM use in pediatric UC patients unlikely to achieve steroid-free remission with mesalamine alone, 2) discovering fundamental new knowledge regarding the role of common genetic and environmental factors ..
  4. Chemoprevention of Colitis-Associated Neoplasia by 5-ASA
    Margie L Clapper; Fiscal Year: 2012
    ..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..
  5. Predicting Response to Standardized Pediatric Colitis Therapy: PROTECT Study
    JEFFREY SAMUEL HYAMS; Fiscal Year: 2013
    ..Longstanding disease carries a high risk of colon cancer. Ideally, UC is adequately controlled with mesalamine, a 5-aminosalicylate with a favorable benefit: risk profile...
  6. Crossover Study on Human Exposure to Phthalates and Male Fertility
    Russ B Hauser; Fiscal Year: 2013
    ..S. population. The source of DBP exposure was Asacol (mesalamine, with enteric coating containing DBP) used to treat inflammatory bowel disease (IBD)...
  7. Targeting Oxidative Stress in Chronic Beryllium Disease
    Lisa A Maier; Fiscal Year: 2013
    ..The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects. ..
  8. HIV, Gut Mucosal Turnover and Inflammation, and the Risk of Colorectal Neoplasia
    Ma Somsouk; Fiscal Year: 2013
    ..are associated with the presence of neoplasia in both HIV+ and HIV- individuals, and (3) to determine whether mesalamine decreases gut epithelial turnover and mucosal inflammation among HIV+ individuals in the context of an ongoing ..
  9. 5ASA REGULATION OF MNSOD IN INTESTINAL CELLS
    John Valentine; Fiscal Year: 2002
    ..The peak onset of IBD is between 15 and 25 years of age and the majority of patients with IBD are under age 40. Mesalamine (5-ASA) is the active ingredient in sulfasalazine and is one of the major therapies use to treat active disease ..
  10. CYTOKINE MODULATION OF INFLAMMATORY BOWEL DISEASE
    GARY VARILEK; Fiscal Year: 2000
    ..E (vit E) and glutathione (GSH)-enhancing agents, and by anti-inflammatory agents, such as glucocorticoids, mesalamine, and cyclosporine...
  11. BIOADHESIVE POLYMERS FOR TREATMENT OF COLON DISEASE
    Jindrich Kopecek; Fiscal Year: 2000
    ..The results of proposed studies will provide a new therapeutic method for the treatment of ulcerative colitis. Moreover, they will be of importance for the development of other colon-specific drug delivery systems. ..
  12. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2003
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  13. Multi-site Trial of Azathioprine Dosing in Crohn Disease
    Stephen Hanauer; Fiscal Year: 2004
    ..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
  14. Randomized Trial of Rosiglitazone for Ulcerative Colitis
    James Lewis; Fiscal Year: 2005
    ..If our hypothesis is correct, this study will serve to establish that ligands for PPARg possess biological activity necessary to modulate the inflammatory response in the intact human colon. ..
  15. Trefoil Factors in GI Cancer Biology
    Steven H Itzkowitz; Fiscal Year: 2010
    ..The results of these studies could provide insights into novel treatment strategies for gastrointestinal malignancies. ..
  16. Maternal Phthalate Exposure and Infertility, Fetal Loss
    Russ Hauser; Fiscal Year: 2007
    ..Since occupational and environmental exposure to phthalates is widespread, detecting even small adverse effects will have large public health significance. ..
  17. STUDY OF REG RECEPTOR-LIGAND BIOLOGY IN GI MUCOSA
    Brian Dieckgraefe; Fiscal Year: 2008
    ..These studies will also provide new insight into the role of Reg IV antagonists and lay the groundwork for development of therapeutic reagents active in gastrointestinal adenocarcinomas. ..
  18. Pilot study on the safety and efficacy of ciprofloxacin for prophylactic preventi
    Hans Herfarth; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  19. NF-kB in the intestinal radiation response
    Laurence Egan; Fiscal Year: 2005
    ..These results will provide mechanistic insight into an important medically relevant problem, amd will point the way towards novel therapies to prevent radiation injury to the intestines. ..
  20. Adenosine in trauma and sepsis
    Gyorgy Hasko; Fiscal Year: 2007
    ..abstract_text> ..
  21. Association of PPAR gamma ligands & colonic neoplasia
    James Lewis; Fiscal Year: 2006
    ..Our results will allow us to translate the existing in vitro and in vivo observations to the intact human colon and could lead to further chemoprevention strategies. ..
  22. TFF3 GENE EXPRESSION IN METASTATIC COLON CANCER
    Steven Itzkowitz; Fiscal Year: 2001
    ..The use of the TFF3 gene to drive expression of suicide genes offers a novel approach which should result in more targetted, safer gene therapy for metastatic colon cancer. ..
  23. Pathologic Markers of Genetic Damage and Disease in IBD
    Melvin Heyman; Fiscal Year: 2005
    ..abstract_text> ..
  24. Analysis of the Chemopreventive Activity of FGN 1
    MARGIE CLAPPER; Fiscal Year: 2004
    ....
  25. OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo
    BRUCE SANDS; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  26. IKK Beta In Intestinal Inflammation
    Laurence Egan; Fiscal Year: 2005
    ..abstract_text> ..
  27. Clinical Approaches to Ileal Pouch Dysfunction
    Bo Shen; Fiscal Year: 2005
    ..The AIMS of study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in IPS. ..
  28. Maternal Pesticide Exposure and Pregnancy Outcomes
    Russ Hauser; Fiscal Year: 2009
    ..Since the etiology of infertility and early pregnancy loss remains largely unexplained, the identification of potential environmental risk factors will have large public health significance. ..
  29. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004
    ..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
  30. Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral Therapy
    Sonia Hernandez diaz; Fiscal Year: 2010
    ..We propose to evaluate the risk of congenital malformations and other adverse pregnancy outcomes following antenatal exposure to ART in a prospective cohort of pregnant women. ..
  31. IMURAN Dose Ranging Study in Crohn's Disease
    BRUCE SANDS; Fiscal Year: 2005
    ..Abstract Not Provided ..